Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,305 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05744739 | Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 8 | Northwestern UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma |
| terminated |
| Phase 2 |
| 7 |
| Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Jun 10, 2026 |
| clinicaltrials |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | terminated | Phase 2 | 7 | University of Southern CaliforniaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05712278 | A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 7 | SanofiINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05824689 | Fluoroquinolone Resistance Prevalence Study(FRE) | terminated | — | 124 | Hackensack Meridian HealthOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06381830 | Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 8 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04250051 | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04758650 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis(MITRAS) | terminated | Phase 2 | 29 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05224661 | Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events(MEASURE) | terminated | — | 303 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05413915 | Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML | terminated | Phase 3 | 8 | Sarit AssoulineOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05515406 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL | terminated | Phase 1 | 9 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT03946332 | Physical Activity for Myeloma Autograft Longitudinal Study(PAMAL) | terminated | N/A | 60 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07082257 | Precision Performance Status Compared With ECOG Performance Status | terminated | — | 41 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT01135329 | Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | terminated | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT01421927 | Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma(REVALLO) | terminated | Phase 1 | 13 | University Hospital, BordeauxOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06271616 | Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | terminated | Phase 2 | 2 | Mayo ClinicOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | terminated | N/A | 200 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02629692 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies | terminated | Phase 1 / Phase 2 | 124 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 10 | May 13, 2026 | clinicaltrials |
| NCT03757221 | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma(IDARA) | terminated | Phase 2 | 55 | University Hospital, CaenOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06566209 | FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis | terminated | — | 2 | Mayo ClinicOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT03547700 | Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | terminated | Phase 1 / Phase 2 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04331119 | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas | terminated | Phase 2 | 17 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05050461 | Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma(LYMPHO-CoVac) | terminated | N/A | 120 | Versailles HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.(MAPtivate-6) | terminated | Phase 1 / Phase 2 | 40 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT03506373 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia | terminated | Phase 2 | 21 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | terminated | Phase 4 | 141 | TakedaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT04639024 | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | terminated | Phase 2 | 3 | Gwynn Long, M.D.OTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06125028 | [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma(LYMFOR) | terminated | Phase 3 | 8 | Pentixapharm AGINDUSTRY | 5 | Apr 28, 2026 | clinicaltrials |
| NCT05268003 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03622775 | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | terminated | Phase 1 / Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05090566 | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | terminated | Phase 2 | 46 | PfizerINDUSTRY | 2 | Apr 24, 2026 | clinicaltrials |
| NCT04435691 | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06163898 | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 4 | CelgeneINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05983965 | Study of Tazemetostat in Lymphoid Malignancies | terminated | Phase 1 | 6 | University of Alabama at BirminghamOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05012124 | Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE | terminated | N/A | 297 | University of WashingtonOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06088654 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 23 | Innate PharmaINDUSTRY | 3 | Apr 14, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 15, 2026source: clinicaltrials